About the Campaign
The Campaign for Patient Access was launched by the American College of Cardiology in December 2009 as a national effort to reverse Medicare physician fee schedule cuts that threatened cardiovascular care. The site provided background on the issue, the ACC's legislative and legal response, resources for patients and practices, a newsroom tracking coverage across the country, and ways for supporters to share their stories and support the campaign.
From the Newsroom
Medicare Meltdown: Access to Health Care in "Critical Condition"
A press release warning that cardiology access was in critical condition due to Medicare payment cuts.
Read more
Cardiology Takes Legal Action Against Medicare
The ACC filed suit against HHS Secretary Kathleen Sebelius over the 2010 Physician Fee Schedule.
Read more
ACC Statement on Health Care Reform
The ACC used the State of the Union address to highlight the need to reverse the Medicare cuts.
Read more
Medicare Patients and Physicians Join Petition Drive
Patients and physicians in Washington, DC joined a petition drive calling on Congress for Medicare reform.
Read moreWhy Payment Cuts Discourage AI in Heart Imaging
Payment reductions can do more than lower a clinician’s income. They can reduce time available for scans and reporting, delay investment in clinical technology and make cardiovascular services harder to sustain. The U.S. Campaign for Patient Access highlighted this risk when Medicare fee schedule cuts began affecting cardiovascular care, but the same funding logic applies wherever patients depend on regulated diagnostic imaging.
Australia needs a careful translation of that lesson. Medicare operates through the Medicare Benefits Schedule, which covers eligible consultations and diagnostic imaging, while private insurers fund many hospital and outpatient services and patients often meet a gap. Changes to rebates, specialist remuneration or hospital funding can have quite different effects. A cardiology service does not need an explicit policy against artificial intelligence for reimbursement pressure to discourage its use.
Payment pressure reaches Australian cardiac imaging
Australian cardiology practices work across a mixed market of public hospitals, private specialists and imaging centres. Medicare rebates support eligible services, private health insurance contributes to inpatient and outpatient costs, and some patients pay gaps or choose bulk-billed services. Diagnostic imaging also depends on separate capital and operating budgets. When professional payments are reduced without a corresponding fall in equipment, staffing or insurance costs, the shortfall must be absorbed somewhere.
That pressure is visible in ordinary schedules around Australia. A patient may see a general practitioner in suburban Sydney or Melbourne, attend a private echocardiography centre in Brisbane, and later review results with a cardiologist using electronic referral systems and My Health Record. Each step consumes staff time. In Adelaide, Perth and regional centres, the available workforce and appointment capacity can be more constrained. AI might reduce repetitive measurement and reporting work, but only if the service can afford to introduce it.
Why lower fees weaken the business case for AI
AI-enabled cardiac imaging can require expenditure on licences, computing infrastructure, system integration, staff training, validation and ongoing quality assurance. A practice must also consider data security and the possibility that a clinically useful tool will not generate enough additional revenue to recover those costs. Reduced reimbursement makes this investment harder to defend, particularly when the expected return depends on higher patient volumes or efficiency gains that may not materialise.
A fee cut can also create an incentive to preserve revenue through faster throughput rather than more cautious interpretation. That creates a perverse position for AI: software capable of detecting subtle abnormalities may save time, but clinicians still need to review the images, confirm measurements and take responsibility for the final report. The organisation pays for the technology, while part of the benefit is realised through additional capacity that may never be funded.
Unpredictability magnifies the problem. Practices facing repeated changes to rebates or remuneration become more cautious about committing to multi-year contracts. Equipment is easier to defer than to replace, and training already paid for can be lost when staff move. A predictable funding base, even a modest one, allows innovation to be planned; a succession of reductions encourages organisations to focus on short-term survival.
| Funding condition | Likely clinical response | Effect on AI adoption |
|---|---|---|
| Stable, realistic reimbursement | Invest in staff, maintenance and carefully tested improvements | AI pilots become part of a planned service |
| Small real-term reduction | Absorb the shortfall through efficiencies | Licences and training may be postponed |
| Large or sudden cut | Reduce sessions, staffing or non-essential services | New technology is difficult to justify |
| Targeted funding for validated tools | Fund integration and quality monitoring | Adoption can expand without weakening essential care |
What AI changes in a real imaging workflow
Useful AI for heart imaging is not a single autonomous diagnosis. It can identify views, flag possible abnormalities, measure ventricular function, support strain analysis and improve the consistency of reports. In echocardiography, for example, automated tools may help standardise image acquisition and quantify ejection fraction. In CT and MRI workflows, they can prioritise studies or highlight features for a cardiologist’s review. These functions reduce duplication while preserving professional oversight.
The value also depends on where the tool sits in the workflow. A system that sends data to a separate cloud service may require new connectivity, cybersecurity controls and arrangements for storing health information. The software must satisfy Australian Therapeutic Goods Administration requirements when it makes a medical-device claim. Integration into existing picture archiving and communication systems, electronic medical records and reporting templates can therefore cost more than the licence itself.
Good implementation should be evaluated for accuracy, safety, equity and time saved. A faster result has little value if it creates missed findings or disadvantages patients whose images were not represented in the training data. Australian hospitals and specialists need evidence from local populations, including Aboriginal and Torres Strait Islander patients and people with varied body sizes, disease patterns and imaging histories. Clinical judgment remains essential.
Rural access makes the funding problem more urgent
AI could help address workforce shortages by supporting image acquisition, preliminary analysis and reporting in locations that have fewer cardiologists or sonographers. It may also allow a general practitioner to obtain clearer guidance on whether a patient needs an urgent referral. These possibilities are particularly relevant in rural and remote Australia, where travel, distance and limited specialist availability can delay diagnosis.
Technology cannot solve a funding shortage by itself. Smaller services may lack stable broadband, technical support and the volume needed to make some commercial products economical. A funded service also needs clinical responsibility, referral pathways and access to a cardiologist when findings are uncertain. If payment reductions force a regional practice to reduce staffing first, it may have less capacity to introduce AI at all.
Australian privacy law, the My Health Records framework and state health-records obligations add safeguards that must be considered when images and patient data move between systems. Clear rules for consent, storage, clinical access and accountability are essential. Reimbursement policy should support those safeguards rather than encourage rushed deployment. Stable public funding for core services remains the foundation on which responsible innovation depends.
A payment model that supports responsible innovation
One approach is to separate essential access funding from the cost of promising new technology. Baseline payments should cover timely consultations, diagnostic imaging and reporting, while a defined innovation pathway supports pilots with transparent evaluation. This can involve grants, shared procurement or additional funding for software that has passed clinical and cybersecurity assessment. It avoids forcing every practice to recover innovation costs from routine patient care.
Reimbursement design should also account for who receives the benefit. If AI reduces the time needed to acquire and interpret a scan, that capacity should support shorter waiting times, more complete follow-up or better access for rural patients. Savings should not disappear into a stretched budget while the clinician performing the review remains underpaid. A fair model recognises professional time, technical work, quality assurance and the occasional need for a human to review an uncertain output.
Evaluation must remain independent and include patients as well as clinicians. Measures could include diagnostic agreement, report turnaround, avoided duplication, patient travel, equity of access and whether clinicians have enough time for complex cases. Procurement decisions should be reversible when evidence is weak. This approach gives AI an opportunity to demonstrate value instead of treating adoption as an ideological choice.
Speak up for access to cardiovascular care
Patients and clinicians can make the consequences of payment policy visible. Patients can write to their federal member of Parliament about proposed changes to imaging services, Medicare rebates or hospital funding, using personal examples about waiting times, travel and out-of-pocket costs. Clinicians can document deferred equipment, staffing shortages and delayed results when those effects are not apparent in headline budget figures.
Evidence belongs in parliamentary inquiries, government consultations and professional submissions, as well as in public advocacy. Clear accounts of how reduced remuneration affects echocardiography, CT, MRI and follow-up care can demonstrate whether savings remain in the health system or are transferred to patients and practices. Patients can also support campaigns for cardiovascular access by sharing how long it took to receive an accurate diagnosis and what happened while care was delayed.
Speak with a federal member of Parliament, submit your experience to relevant consultations and share the story of how payment decisions affected your cardiovascular care. A strong public record can help preserve essential services while giving clinically validated AI a fair chance to earn its place.
Campaign for Patient Access